Another Clinical Trial Commenced for a Product Based on iBioLaunch Technology
iBio, Inc. announced today that the U.S. Food and Drug Administration accepted another Investigational New Drug application filed for a product candidate made with the Company's proprietary, transformative technology, the iBioLaunch™ technology platform.
Read more on Business Wire via Yahoo! Finance
Orignal From: Another Clinical Trial Commenced for a Product Based on iBioLaunch Technology
Post a Comment